My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Motolimod (VTX-2337)
    Motolimod (VTX-2337)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1872
    CAS #: 926927-61-9Purity ≥98%

    Description: Motolimod (also known as VTX-2337) is a novel, selective and potent small molecule agonist of the Toll-like receptor (TLR) 8 with EC50 of 100 nM, it displays > 50-fold selectivity over TLR7 and has potential immunostimulating and anticancer activities. Motolimod is currently under clinical development as an immunotherapy for multiple oncology indications such as ovarian cancer and squamous cell carcinoma of the head and neck. TLR8 is located in the endosome where it functions in the recognition of foreign nucleic acids from intracellular pathogens. TLR8 has emerged as a potential target for anticancer immunotherapies. 

    References: Clin Cancer Res. 2012 Jan 15;18(2):499-509; J Clin Oncol 31, 2013 (suppl; abstr 3077).

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)458.6 
    CAS No.926927-61-9 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 55 mg/mL (119.9 mM) 
    Water: <1 mg/mL
    Ethanol: 15 mg/mL (32.7 mM)
    Synonyms VTX-2337; VTX 2337; VTX2337; VTX-378; VTX 378; VTX378

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: VTX-2337 (Motolimod) stimulates the production of both TNFα with EC50 of 140 nM and IL-12 with EC50 of 120 nM in PBMCs. In monocytes and mDCs, VTX-2337 selectively induces the production of TNFα and IL-12 via NF-κB activation. VTX-2337 also stimulates IFNγ production from NK cells, augments the lytic function of NK cells and enhances ADCC.

    Kinase Assay: The activity of specific TLR agonists is assessed using the secretory embryonic alkaline phosphatase (SEAP) reporter gene that is linked to NF-κB activation in response to TLR stimulation. Measurement of SEAP activity using the Quanti-blue substrate (InvivoGen) after TLR agonist treatment is carried out. 

    Cell Assay: PBMCs or purified NK cells are prepared as previously described, and the purity of NK cells was approximately 99%. NK cell–mediated cytotoxicity is assessed by Calcein AM release from labeled target cells. In brief, PBMCs or purified NK cells are cultured for 48 hours in RPMI medium in the presence of VTX-2337 (167 or 500 nmol/L) before incubation with target cells.

    In VivoIn an ovarian cancer mouse model, TX-2337 enhances the effect of pegylated liposomal doxorubicin (PLD); In male cynomolgus monkeys, VTX-2337 induced IL-1β and IL-18 production.
    Animal model Mouse model
    Formulation & Dosage 1 or 10 mg/kg, s.c. injection
    ReferencesClin Cancer Res. 2012 Jan 15;18(2):499-509; J Clin Oncol 31, 2013 (suppl; abstr 3077). 

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Motolimod (VTX-2337)

    VTX-2337 is a selective and potent TLR8 agonist that induces TNFα and IL-12 production.  2012 Jan 15;18(2):499-509.

     Motolimod (VTX-2337)

    VTX-2337 selectively induces the production of TNFα and IL-12 and activates NF-κB phosphorylation in monocytes and mDCs, but not pDCs.  2012 Jan 15;18(2):499-509.

     Motolimod (VTX-2337)

    VTX-2337 stimulates IFNγ production from NK cells.  2012 Jan 15;18(2):499-509.

     Motolimod (VTX-2337)

    VTX-2337 enhances the NK cell lytic activity and augments rituximab- and trastuzumab-mediated ADCC.  2012 Jan 15;18(2):499-509.

     Motolimod (VTX-2337)

    VTX-2337 enhances ADCC in donors with different SNP on FcγR3A.  2012 Jan 15;18(2):499-509.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?